


Innovations powered by X<sup>BIO</sup>™ technology

# Investor Presentation

Judith Mitchell  
Managing Director  
28 January 2021




**NEXT SCIENCE®**


# NXS at a glance

- Currently the only company in the world with approved products that resolve biofilm based infections in humans
- 3 products in the US human healthcare market
- Additional regulatory approvals of CE Mark and TGA to support revenue growth through market access to Australia, UK, Germany, Netherlands, Nordic countries and France
- New product XPerience to be launched in the US in 1H 2021, post FDA Clearance. This is the first no rinse anti-microbial solution for use in surgery to prevent Surgical Site Infection (SSI), a total global addressable market of >\$15B per annum


## Key Statistics



Treated over  
150,000 patients




31 patents awarded



All Products are effective in removing key community acquired pathogens:


- COVID 19
- MRSA (Golden Staphj)
- Candida
- Pseudomonas Aeruginosa
- E.Coli

US Hospitals Using Xbio Products



\*Represents 10% of total Hospitals and Ambulatory Surgery Centres

Patients treated with Xbio Products



# The opportunities – prevention and treatment

Expanding into infection prevention significantly enhances addressable market opportunities

## Prevention products in market

- 1) SURGICAL SITE INFECTION
- 2) Prosthetic Joint Infection
- 3) Acne


## Treatment products in market

- 1) SURGICAL SITE INFECTION
- 2) Prosthetic Joint Infection
- 3) Acne and skin health
- 4) Chronic Wounds

## Products in development

- 5) Chronic Middle Ear Infection
- 6) Chronic Sinusitis

## CHRONIC BACTERIAL INFECTIONS: MEDICAL BIOFILMS



## Research underway

- 7) Skin health
- 8) Lung infections including pneumonia and cystic fibrosis
- 9) Dental implants, periodontitis
- 10) Catheter infections
- 11) Implant infections

## Potential for future research

- 12) Endocarditis
- 13) Kidney stones
- 14) Biliary tract infection
- 15) Urinary tract infection
- 16) Vaginosis
- 17) Osteomyelitis





Across our broad portfolio of commercial opportunities, XPerience is our number 1 priority in 2021

# 2020 Highlights

- Returned revenue to growth in Q4 (Q4 2020 on Q4 2019 74% growth). Q4 run rate expected to continue in 1H 2021 (excluding XPerience) ✓
- 2 CE Marks awarded (Bactisure and BlastX) ✓
- 1<sup>st</sup> TGA approval (Bactisure) for Australia and Australian launch ✓
- Patent portfolio increased to 31 patents ✓
- Grew direct Surgical Sales team and contract sales force to 200 people in the US ✓
- Capital raise of \$A15M successfully completed to fund the commercialisation of XPerience in the US (1H 2021) and support the company's long term growth strategy ✓



# Products contributing to 2020 Revenue

Product	Commercial Pathway	Application	Total addressable market
Bactisure Surgical Lavage 	Global Distribution through Zimmer Biomet	Treatment of infected surgical cavities & implants	500,000 – 1 Million patients globally annually
BlastX Antimicrobial Wound Gel 	Global Distribution 3M KCI Advanced Wound Care*	Treatment of chronic wounds: Foot & Leg Ulcers, Bedsores and Pressure Ulcers	10 Million patients globally 6 million patients (US only) annually
SurgX Sterile Antimicrobial Wound Gel 	NXS distribution network in the US	Prevention of infection in surgical incisions. Used in the Operating room	48 Million surgeries in the US annually
Acne Gel and Cream 	AST & tbh Skincare	Topical treatment of acne	Online & Clinic market


- ✓ First no-rinse antimicrobial solution to be offered to address the global \$15B pa market of surgical site infection prevention



- ✓ No rinse out required
- ✓ Non toxic
- ✓ Broad spectrum efficacy against bacteria, viruses and fungi

**NEXT SCIENCE®**



# XPerience Update



FDA requested additional testing in September, 2020. Test results were submitted in December, 2020. Launch expected 1H 2021

- ✓ No change to current surgical protocols
- ✓ Easy to use and adopt
- ✓ Multiple hours of protection

# 2021 Pipeline of new product launches

Product	Target Launch	Application	Total addressable market	Commercial Pathway
XPerience No rinse anti microbial solution 	1H 2021	Last surgical rinse for open surgeries prior to closing to remove biofilm and incumbent viruses and bacteria, preventing post operative infection	First marketing wave will address the US Orthopaedic market of 5.4M surgeries Value \$1B pa	Next Science Direct distribution in the US market
Biofilm effective Disinfectant for Industrial Hard Surfaces	2H 2021	Walls, floors, furniture and fittings in environments that needs antimicrobial coverage	Global surface disinfectant market \$800 Million pa	Licensing agreement for royalty pathway
TorrentX Wound Wash 	1H 2021	Topical wash for treatment of chronic wounds: foot & leg ulcers in preparation for a tissue substitute	The product is used as a cleanser for any chronic wound including leg and foot ulcers	In the US selling through Triad Life Sciences bundled with their new skin substitute

# NEXT SCIENCE®

Break through biofilm.

investorqueries@nextscience.com | +61 2 8607 5125 | NextScience.com

**Authorised by the Next Science Board**  
**January 28<sup>th</sup>, 2021**

Suite 1902 Tower A  
821 Pacific Highway  
Chatswood NSW 2067

Additional biofilm education can be found at: [biofilm.healthcare](https://biofilm.healthcare)